Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2018-04-26 M&A Activity
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
M&A Activity Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a strategic alliance and licensing agreement between Adocia and Tonghua Dongbao regarding drug development and commercialization rights in China. It details financial terms like upfront payments, milestone payments, and royalties. This type of announcement, detailing a significant business transaction (licensing/partnership) that impacts future financing and operations, fits best under the 'Capital/Financing Update' category, as it involves significant financial commitments and rights transfer, although it is not a direct capital raise. However, looking closely at the definitions, it is a major business development announcement. Since there is no specific category for 'Strategic Alliance' or 'Licensing Agreement', I must choose the closest fit. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a formal announcement of a major business deal. Given the options, 'CAP' (Capital/Financing Update) covers significant financial structuring/agreements, or 'RNS' (Regulatory Filings/General Announcement) as a fallback. Since the core of the announcement is the financial structure of the deal (payments, royalties), CAP is a strong candidate. However, 'TAR' (M&A Activity) is for mergers/takeovers, which this is not. Given the nature of a press release announcing a major partnership with financial implications, and lacking a dedicated 'Partnership' code, 'RNS' (Regulatory Filings/General Announcement) is the safest general classification for a press release detailing a strategic business development that doesn't fit the highly specific financial report codes. Upon re-evaluation, major licensing deals often fall under general business updates. Since it is a press release announcing a major strategic business development, and not a formal regulatory filing like a 10-K or a specific financial report, RNS is the most appropriate general category for a press release of this nature that doesn't fit the other specific financial/reporting codes.
2018-04-26 French
Document availability communications / Methods of making financial reports or updated prospectuses available
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and its primary purpose is to announce that Adocia has filed its "2017 Reference Document" with the AMF (French regulator) on April 19, 2018. The text states that the Reference Document includes the annual financial report, management report, and governance report. Crucially, the document itself is not the full report but an announcement *about* the report's publication. According to Rule #2, when a document is short and announces the release or availability of a report, it should be classified as a Report Publication Announcement (RPA). The document length (3383 chars) supports this interpretation, as it is merely a notification.
2018-04-19 English
Communiqués de mise à disposition de documents / Modalités de mise à disposition document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a press release titled "Adocia annonce la mise à disposition de son document de référence pour l'année 2017" (Adocia announces the availability of its 2017 reference document). It explicitly states that the 2017 reference document (document de référence 2017) has been filed with the AMF (Autorité des marchés financiers) and is now available online. The document length is short (3333 characters) and its primary function is to announce the publication/availability of a larger report (which includes the annual financial report and corporate governance report). According to Rule #2 (The 'MENU VS MEAL' Rule), when a short document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2018-04-19 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is a press release ('COMMUNIQUE DE PRESSE') published on April 16, 2018, detailing the total number of shares and voting rights as of March 31, 2018. This type of mandatory disclosure, referencing the French Commercial Code (Code de Commerce) and AMF regulations (Autorité des Marchés Financiers), specifically relates to changes in the capital structure or ownership notification thresholds. While it involves share counts, it is not a general capital change announcement (SHA) or a major shareholding notification (MRQ) which typically reports an individual crossing a threshold. Instead, it is a periodic statement of the total share count. This information is often required in conjunction with proxy statements or general corporate updates. Given the options, the closest fit for a periodic notification regarding share capital and voting rights, especially when it's a formal regulatory disclosure that doesn't fit perfectly into the other specific categories, is often categorized under general regulatory filings or specific capital/share announcements. Since it explicitly states the number of shares and voting rights, it is a direct disclosure related to the company's share structure. However, none of the codes perfectly match a 'Total Share Count Disclosure'. It is not a Director's Dealing (DIRS), a Dividend Notice (DIV), or a general Earnings Release (ER). It is a formal regulatory disclosure. Comparing it to the definitions, it is most closely related to the mechanics of share ownership, but it is not a notification of a *change* in a major shareholder (MRQ) or a general capital change (SHA). Since it is a formal, periodic regulatory disclosure mandated by the AMF, and it doesn't fit the other specific categories like DIRS, DIV, or ER, it defaults to a general regulatory filing category. However, the content is highly specific to share capital. Let's re-evaluate: It reports the total number of shares and voting rights. This is a fundamental piece of information often required for shareholder meetings or regulatory compliance. If we consider 'SHA' (Share Issue/Capital Change), this document reports the *current state* of the capital, not necessarily an *issue* or *change* event, although the number might have changed since the last report. Given the context of mandatory regulatory reporting of share counts, and lacking a specific 'Share Capital Status Report' code, 'RNS' (Regulatory Filings) is the safest fallback for a mandatory, non-financial, non-management announcement. However, if we interpret 'SHA' broadly as relating to the share capital structure, it might fit. Given the strict definitions, and that this is a routine regulatory update on the capital base, 'RNS' is the most appropriate general regulatory category when a more specific one (like MRQ for crossing a threshold) is not met.
2018-04-16 French
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated April 16, 2018, announcing the 'Total number of outstanding shares as well as its voting rights as of March 31, 2018.' It explicitly cites French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter) requiring this disclosure. This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure transparency. While it is a press release, its core content is a formal declaration of voting rights and share count, which aligns closely with announcements concerning capital structure or general regulatory disclosures. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most precise fit for a formal declaration of total voting rights, even if it's not the result of a specific vote, as it deals directly with the mechanics of voting rights calculation. It is not a general earnings release (ER), a capital change announcement (CAP/SHA), or a director's dealing (DIRS). Since it is a formal, mandated disclosure of voting rights mechanics, DVA is the best classification.
2018-04-16 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the initiation of a Phase 1 clinical study for a new drug combination (BioChaperone Pramlintide Insuline). It details the study objectives (pharmacokinetics, safety, tolerance), the timeline (expected completion Q3 2018), and provides background on the drug and the company's pipeline. This content structure—a formal announcement of a significant corporate/clinical event, often released to the public and media—is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it's a mandatory disclosure. Since it is a press release announcing a clinical trial initiation, which is a material event for a biotech company, it fits best under the general category for regulatory announcements that aren't specifically financial reports (10-K, IR) or management changes (MANG). Given the options, 'Regulatory Filings' (RNS) serves as the best general category for material, non-financial, non-meeting-related corporate updates, although 'Earnings Release' (ER) is sometimes used broadly for major operational updates if no specific category fits. However, as this is purely clinical/R&D news, RNS is the most appropriate fallback for a material announcement not covered elsewhere.
2018-04-16 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.